Global Fc Fusion Therapeutics Market Report 2021: Current Market Landscape & Therapies Forecasts to 2030
Saturday, December 11, 2021
DUBLIN, Dec. 3, 2021 /PRNewswire/ -- The "Fc Fusion Therapeutics Market - Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
The "Fc Fusion Therapeutics Market Report" report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies till 2030. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
One of the key objectives of the report was to estimate the existing market size and the future growth opportunities for Fc fusion therapeutics, over the next few years. Based on multiple parameters, such as target patient population, likely adoption rate and the annual treatment cost, we have provided informed estimates on the evolution of the market for the period 2021-2030.
Since the approval of Enbrel, a recombinant human tumor necrosis factor (TNF) receptor-Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion therapies have evolved into a prominent class of therapeutics. Currently, 13 Fc fusion drugs are commercially available, while around 50 molecules are under development for various disease indications.
Some of the Fc fusion therapeutics including Arcalyst (recurrent pericarditis, March 2021), Reblozyl (beta-thalassemia, September 2020) and Eylea (diabetic retinopathy, May 2019) were approved recently. These molecules combine the beneficial pharmacological properties of biologically active ligands with the properties of the crystallizable fragment (Fc) domain of an immunoglobulin G (IgG).
It is worth highlighting that these advanced variants of immunoglobulin derived therapeutic candidates are protected from lysosomal degradation once they are taken up by endothelial cells and later released back into the bloodstream by binding of the Fc-fragment to FcRn receptors present in endosomes. This prolongs the exposure of the pharmacologically active moieties to the target tissue thereby, increasing their therapeutic efficacy.
Given their ability to extend the serum half-life of biologically active proteins, these disease-modifying interventions find applications across different therapeutic areas (including but not limited to oncological disorders, neurological disorders, respiratory disorders, rare genetic disorders).
Presently, several drug developers are actively engaged in the development of novel Fc fusion therapies with enhanced efficacy. The research in this field is focused on improving the stability and solubility of pharmacologically active moiety, thereby, improving its therapeutic potential.
Further, several big pharma players have demonstrated interest in Fc fusion therapeutics and are investing both time and capital in this domain. The activity in this segment of the industry has also attracted the attention of both private and public sector investors/investment funds, which have extended financial support to the initiatives of capable developer companies.
Moreover, the market has witnessed substantial partnership activity over the last few years. Given the ongoing efforts and the encouraging clinical trial results, the Fc fusion therapies market is poised to witness healthy growth as more drug candidates get approved and marketed over the coming decade.
Key Questions Answered
-- Who are the leading industry players involved in the development of Fc
-- Which geographies are the most active in conducting clinical trials on
Fc fusion therapeutics?
-- Which are the leading funding organizations providing grants for Fc
-- Which partnership models are commonly adopted by industry stakeholders
in the development of Fc fusion therapeutics?
-- How is the current and future market opportunity likely to be
distributed across key market segments?
Amongst other elements, the report includes:
-- A detailed assessment of the current market landscape of Fc fusion
therapeutics, providing information on phase of development (marketed,
clinical and pre-clinical) of lead candidates, type of fusion molecule
(antibody based, cytokine based, enzyme based, growth factor based,
peptide based, receptor ECD based and others), target gene, therapeutic
area(s), target disease indication(s), type of therapy (combination
therapy and monotherapy), route of administration (intravenous,
intravitreal, oral and subcutaneous) and dosing frequency. In addition,
the chapter includes information on the drug developer(s), highlighting
their year of establishment, company size, and location of headquarters.
-- Elaborate profiles of key players involved in the development of Fc
fusion therapeutics. Each profile features a brief overview of the
company, its financial information (if available), information on
product portfolio, recent developments and an informed future outlook.
-- An in-depth analysis of completed, ongoing and planned clinical studies
of various Fc fusion therapeutics, based on several relevant parameters,
such as trial registration year, trial phase, study design, type of
masking, type of intervention model, emerging focus area, leading
industry sponsors/collaborators (in terms of number of trials
conducted), popular indications, popular interventions and regional
distribution of trials.
-- A study of the various grants that have been awarded to research
institutes engaged in conducting projects related to Fc fusion
therapeutics, between 2010 and 2021 (till May), including analyses based
on several relevant parameters, such as year of grant award, amount
awarded, administering institute center, support period, type of grant
application, purpose of grant award, activity code and emerging focus
areas. In addition, it highlights the popular NIH departments, prominent
program officers, and popular recipient organizations (in terms of
number of grants awarded).
-- A detailed review of close to 1,135 peer-reviewed, scientific articles
related to Fc fusion therapeutics, which have been published between
2010 and 2021 (till August). It discusses the trends across parameters,
such as year of publication, emerging focus areas, target therapeutic
area, leading authors, and key journals (in terms of number of articles
published in this domain).
-- An in-depth analysis of the patents that have been filed/granted related
to Fc fusion therapeutics, since 2018. It includes information on
various parameters, such as patent publication year, type of patent,
geographical location/patent jurisdiction, patent age, CPC symbols,
emerging focus areas, and the leading/academic players (in terms of
number of patents filed). In addition, it includes a patent benchmarking
analysis and a detailed valuation analysis.
-- An analysis of the partnerships established between various stakeholders
in this domain, during the period 2016-2021 (till August), covering
product development and commercialization, R&D agreements,
mergers/acquisitions, clinical trial agreements, and other relevant
types of deals.
-- A case study on the Fc protein engineered and glycoengineered antibodies
that are either marketed or being developed based on multiple of
relevant parameters, such as phase of development, target disease
indication, therapeutic area, type of Fc engineering, impact of Fc
engineering, route of administration, and type of therapy. It also
highlights the players involved in the development of these Fc protein
and glycoengineered antibodies.
For more information about this report visit https://www.researchandmarkets.com/r/fa7as1
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-fc-fusion-therapeutics-market-report-2021-current-market-landscape--therapies-forecasts-to-2030-301436996.html
SOURCE Research and Markets
||ThunderSoft Announces New Smart Cockpit Solution Based on Qualcomm SA8295 at CES 2022 | Jan 14, 2022
||E.B. Williams' new book "The Kite Documents" is a whimsical read on the history and genealogy of the Daus colony | Jan 14, 2022
||Unique Opportunity to Acquire Exclusive Rights To the "Ebony" and "Ebone" Names | Jan 14, 2022
||CareAR, a Xerox Company, Continues Growth with Acquisition of MagicLens, a 3D Visualization and Augmented Reality Platform | Jan 14, 2022
||Global Smart Card in Healthcare Market (2021 to 2027) - by Product, Component and Region | Jan 14, 2022
||GrowPath the Choice for Georgia Eminent Domain Law Firm Case Management Software | Jan 14, 2022
||Outlook on the Agriculture Sensor Global Market to 2028 - Size, Share & Trends Analysis Report | Jan 14, 2022
||Cast Resin Dry Type Transformer Market to Reach $5.0 Bn, Globally, by 2030 at 5.3% CAGR: Allied Market Research | Jan 14, 2022
||Price of Uranium Expected to Rally In Next 5 Years as a Shift to Nuclear Energy is Inevitable | Jan 14, 2022
||Seeing Machines and Ambarella collaborate on integrated forward-facing ADAS and in-cabin occupant and driver monitoring system solutions | Jan 14, 2022